Table 3.

Selected Major Clinical Studies Involving HER2-targeted Therapies.

Clinical Study Trastuzumab-Anthracycline Interval Monitoring Cardiac Risk-related Exclusion Criteria Clinical Heart Failure (%) LV Dysfunction (%) Partial Reversibility Reported
Slamon et al.107 Concurrent None pre-specified None 16% 27% Yes
Romond et al.109 3 weeks MUGA LVD, HTN, ANY 4.1% 19%* Yes
Polman et al.118 3 weeks MUGA or ECHO LVD, HTN, ANY 2% 19% Yes
Goldhirsch et al.119 3 months MUGA or ECHO LVD, HTN, ANY 0.8% 7.2% Yes
Tolaney et al.120 No anthracycline given MUGA or ECHO LVD, HTN, ANY 0.5% 3.2% Yes
*Discontinued drug due to cardiac adverse event.

ANY, any sign or symptom of cardiac disease; ECHO, echocardiography; HTN, hypertension; LVD, left ventricular dysfunction.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2019 April; 10(2): e0012. ISSN: 2076-9172
Published online 2019 April 18. doi: 10.5041/RMMJ.10366.